

Martin J B Van Den Bent

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/339988/martin-j-b-van-den-bent-publications-by-year.pdf>
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

440 papers	54,570 citations	95 h-index	229 g-index
471 ext. papers	64,603 ext. citations	6 avg, IF	7.23 L-index

#	Paper	IF	Citations
440	MGMT promoter methylation determined by the MGMT-STP27 algorithm is not predictive for outcome to temozolomide in IDH-mutant anaplastic astrocytomas.. <i>Neuro-Oncology</i> , 2022 ,	1	1
439	Development and external validation of a clinical prediction model for survival in patients with IDH wild-type glioblastoma.. <i>Journal of Neurosurgery</i> , 2022 , 1-10	3.2	1
438	Prescription preferences of antiepileptic drugs in brain tumor patients: An international survey among EANO members.. <i>Neuro-Oncology Practice</i> , 2022 , 9, 105-113	2.2	0
437	Isocitrate Dehydrogenase Mutant Grade II and III Glial Neoplasms. <i>Hematology/Oncology Clinics of North America</i> , 2022 , 36, 95-111	3.1	1
436	Noninvasive differentiation of molecular subtypes of adult nonenhancing glioma using MRI perfusion and diffusion parameters.. <i>Neuro-Oncology Advances</i> , 2022 , 4, vdac023	0.9	2
435	DNA methylation-based age acceleration observed in IDH wild-type glioblastoma is associated with better outcome-including in elderly patients.. <i>Acta Neuropathologica Communications</i> , 2022 , 10, 39	7.3	1
434	The impact of different volumetric thresholds to determine progressive disease in patients with recurrent glioblastoma treated with bevacizumab.. <i>Neuro-Oncology Advances</i> , 2022 , 4, vdac032	0.9	
433	Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline. <i>Neuro-Oncology</i> , 2022 , 24, 331-357	1	0
432	Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline. <i>Neuro-Oncology</i> , 2022 , 24, 358-383	1	1
431	Radiotherapy Combined With Nivolumab or Temozolomide for Newly Diagnosed Glioblastoma With Unmethylated MGMT Promoter: An International Randomized Phase 3 Trial.. <i>Neuro-Oncology</i> , 2022 ,	1	6
430	A qualitative study on the challenges health care professionals face when caring for adolescents and young adults with an uncertain and/or poor cancer prognosis.. <i>ESMO Open</i> , 2022 , 7, 100476	6	1
429	Radiation Therapy for Brain Metastases: ASCO Guideline Endorsement of ASTRO Guideline.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2200333	2.2	0
428	Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline.. <i>Journal of Clinical Oncology</i> , 2021 , JCO2102036	2.2	10
427	Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline.. <i>Journal of Clinical Oncology</i> , 2021 , JCO210231422	2.2	10
426	A Phase 2 Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma. <i>Clinical Cancer Research</i> , 2021 ,	12.9	2
425	Dabrafenib plus trametinib in patients with BRAF-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial. <i>Lancet Oncology</i> , 2021 ,	21.7	22
424	Deep-learning-based synthesis of post-contrast T1-weighted MRI for tumour response assessment in neuro-oncology: a multicentre, retrospective cohort study. <i>The Lancet Digital Health</i> , 2021 , 3, e784-e794	14.4	6

423	The relationship between mental fatigue, cognitive functioning, and employment status in patients with low-grade glioma: a cross-sectional single-center study. <i>Disability and Rehabilitation</i> , 2021 , 1-7	2.4	1
422	Patients with primary brain tumors and COVID-19: A report from the Dutch Oncology COVID-19 Consortium. <i>Neuro-Oncology</i> , 2021 ,	1	1
421	Prognostic validation and clinical implications of the EANO ESMO classification of leptomeningeal metastasis from solid tumors. <i>Neuro-Oncology</i> , 2021 , 23, 1100-1112	1	17
420	Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations. <i>Acta Neuropathologica</i> , 2021 , 141, 945-957	14.3	9
419	First-line antiepileptic drug treatment in glioma patients with epilepsy: Levetiracetam vs valproic acid. <i>Epilepsia</i> , 2021 , 62, 1119-1129	6.4	9
418	Adolescents and Young Adults Living With an Uncertain or Poor Cancer Prognosis: The "New" Lost Tribe. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021 , 19, 240-246	7.3	4
417	Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma. <i>Neuro-Oncology</i> , 2021 , 23, 1547-1559	1	7
416	Effect of antiepileptic drugs in glioma patients on self-reported depression, anxiety, and cognitive complaints. <i>Journal of Neuro-Oncology</i> , 2021 , 153, 89-98	4.8	3
415	Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastoma. <i>European Journal of Cancer</i> , 2021 , 147, 1-12	7.5	2
414	Prognostic factors in leptomeningeal metastases. <i>Neuro-Oncology</i> , 2021 , 23, 1208-1209	1	
413	Evidence-based recommendations on categories for extent of resection in diffuse glioma. <i>European Journal of Cancer</i> , 2021 , 149, 23-33	7.5	17
412	Comprehensive Assessment of Incidence, Risk Factors, and Mechanisms of Impaired Medical and Psychosocial Health Outcomes among Adolescents and Young Adults with Cancer: Protocol of the Prospective Observational COMPRAYA Cohort Study. <i>Cancers</i> , 2021 , 13,	6.6	1
411	Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study. <i>Lancet Oncology</i> , 2021 , 22, 813-823	21.7	24
410	The effectiveness of antiepileptic drug treatment in glioma patients: lamotrigine versus lacosamide. <i>Journal of Neuro-Oncology</i> , 2021 , 154, 73-81	4.8	2
409	Radiographic read paradigms and the roles of the central imaging laboratory in neuro-oncology clinical trials. <i>Neuro-Oncology</i> , 2021 , 23, 189-198	1	3
408	Memory in low-grade glioma patients treated with radiotherapy or temozolomide: a correlative analysis of EORTC study 22033-26033. <i>Neuro-Oncology</i> , 2021 , 23, 803-811	1	6
407	CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design. <i>Neuro-Oncology</i> , 2021 , 23, 457-467	1	18
406	A basic review on systemic treatment options in WHO grade II-III gliomas. <i>Cancer Treatment Reviews</i> , 2021 , 92, 102124	14.4	17

405	EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. <i>Nature Reviews Clinical Oncology</i> , 2021 , 18, 170-186	19.4	204
404	Long-term employment status and the association with fatigue in patients with grade II glioma. <i>Journal of Rehabilitation Medicine</i> , 2021 , 53, jrm00198	3.4	2
403	Role of surgery for glioblastoma: response to letters from Dr. Gerritsen and his colleagues and Dr. Vargas Lopez. <i>Neuro-Oncology</i> , 2021 , 23, 506-507	1	
402	The state of neuro-oncology during the COVID-19 pandemic: a worldwide assessment. <i>Neuro-Oncology Advances</i> , 2021 , 3, vdab035	0.9	0
401	Objective neurocognitive functioning and neurocognitive complaints in patients with high-grade glioma: Evidence of cognitive awareness from the European Organisation for Research and Treatment of Cancer brain tumour clinical trials. <i>European Journal of Cancer</i> , 2021 , 144, 162-168	7.5	3
400	Mapping tumour heterogeneity with pulsed 3D CEST MRI in non-enhancing glioma at 3T. <i>Magnetic Resonance Materials in Physics, Biology, and Medicine</i> , 2021 , 1	2.8	4
399	Establishing anchor-based minimally important differences for the EORTC QLQ-C30 in glioma patients. <i>Neuro-Oncology</i> , 2021 , 23, 1327-1336	1	4
398	Neurocognitive functioning and radiologic changes in primary CNS lymphoma patients: results from the HOVON 105/ALLG NHL 24 randomized controlled trial. <i>Neuro-Oncology</i> , 2021 , 23, 1315-1326	1	1
397	MMSE is an independent prognostic factor for survival in primary central nervous system lymphoma. <i>Journal of Neuro-Oncology</i> , 2021 , 152, 357-362	4.8	3
396	Treatment of anaplastic gliomas: evidences and controversies. <i>Current Opinion in Oncology</i> , 2021 , 33, 621-625	4.2	0
395	The Erasmus Glioma Database (EGD): Structural MRI scans, WHO 2016 subtypes, and segmentations of 774 patients with glioma. <i>Data in Brief</i> , 2021 , 37, 107191	1.2	1
394	Assessment of imaging biomarkers in the follow-up of brain metastases after SRS. <i>Neuro-Oncology</i> , 2021 , 23, 1983-1984	1	1
393	Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma - Authors' reply. <i>Lancet Oncology</i> , 2021 , 22, e346	21.7	0
392	The evolving role of neurosurgery for central nervous system metastases in the era of personalized cancer therapy. <i>European Journal of Cancer</i> , 2021 , 156, 93-108	7.5	5
391	Detection of Aneuploidy in Cerebrospinal Fluid from Patients with Breast Cancer Can Improve Diagnosis of Leptomeningeal Metastases. <i>Clinical Cancer Research</i> , 2021 , 27, 2798-2806	12.9	2
390	Extent of radiological response does not reflect survival in primary central nervous system lymphoma. <i>Neuro-Oncology Advances</i> , 2021 , 3, vdab007	0.9	1
389	Subacute neurological deficits and respiratory insufficiency due to intrathecal methotrexate. <i>Journal of Clinical and Translational Research</i> , 2021 , 7, 809-810	1.1	0
388	Topographical Mapping of 436 Newly Diagnosed IDH Wildtype Glioblastoma With vs. Without MGMT Promoter Methylation. <i>Frontiers in Oncology</i> , 2020 , 10, 596	5.3	7

387	Validation of diffusion MRI phenotypes for predicting response to bevacizumab in recurrent glioblastoma: post-hoc analysis of the EORTC-26101 trial. <i>Neuro-Oncology</i> , 2020 , 22, 1667-1676	1	4
386	Response assessment in paediatric low-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. <i>Lancet Oncology</i> , 2020 , 21, e305-e316	21.7	43
385	Consensus recommendations for a dynamic susceptibility contrast MRI protocol for use in high-grade gliomas. <i>Neuro-Oncology</i> , 2020 , 22, 1262-1275	1	38
384	Gray Areas in the Gray Matter: Mutations in Glioma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020 , 40, 1-8	7.1	5
383	Phase 0 and window of opportunity clinical trial design in neuro-oncology: a RANO review. <i>Neuro-Oncology</i> , 2020 , 22, 1568-1579	1	15
382	Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases. <i>Neuro-Oncology</i> , 2020 , 22, 757-772	1	45
381	"Real world" use of a highly reliable imaging sign: "T2-FLAIR mismatch" for identification of IDH mutant astrocytomas. <i>Neuro-Oncology</i> , 2020 , 22, 936-943	1	28
380	Gender issues from the perspective of health-care professionals in Neuro-oncology: an EANO and EORTC Brain Tumor Group survey. <i>Neuro-Oncology Practice</i> , 2020 , 7, 249-259	2.2	
379	cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. <i>Acta Neuropathologica</i> , 2020 , 139, 603-608	14.3	170
378	Urgent Considerations for the Neuro-oncologic Treatment of Patients with Gliomas During the COVID-19 Pandemic. <i>Neuro-Oncology</i> , 2020 ,	1	47
377	Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. <i>Neuro-Oncology</i> , 2020 , 22, 1073-1113	1	178
376	Calculating the net clinical benefit in neuro-oncology clinical trials using two methods: quality-adjusted survival effect sizes and joint modeling. <i>Neuro-Oncology Advances</i> , 2020 , 2, vdaa147	0.9	1
375	Health-related quality of life after chemotherapy with or without rituximab in primary central nervous system lymphoma patients: results from a randomised phase III study. <i>Annals of Oncology</i> , 2020 , 31, 1046-1055	10.3	3
374	Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients. <i>Neuro-Oncology</i> , 2020 , 22, 601-612	1	12
373	CTNI-29. CODEL: PHASE III TRIAL OF RT ALONE, RT PLUS TMZ, OR TMZ ALONE FOR NEWLY-DIAGNOSED, 1p/19q CODELETED ANAPLASTIC OLIGODENDROGLIOMA. ANALYSIS FROM THE INITIAL STUDY DESIGN. (NCCTG N0577, ALLIANCE). <i>Neuro-Oncology</i> , 2020 , 22, ii48-ii49	1	3
372	Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria. <i>Neuro-Oncology</i> , 2020 , 22, 515-523	1	58
371	Toward a standard pathological and molecular characterization of recurrent glioma in adults: a Response Assessment in Neuro-Oncology effort. <i>Neuro-Oncology</i> , 2020 , 22, 450-456	1	14
370	Molecular Evolution of Wild-Type Glioblastomas Treated With Standard of Care Affects Survival and Design of Precision Medicine Trials: A Report From the EORTC 1542 Study. <i>Journal of Clinical Oncology</i> , 2020 , 38, 81-99	2.2	43

369	EGFR mutations are associated with response to depatux-m in combination with temozolomide and result in a receptor that is hypersensitive to ligand. <i>Neuro-Oncology Advances</i> , 2020 , 2, vdz051	0.9	6
368	INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. <i>Neuro-Oncology</i> , 2020 , 22, 684-693	1.6	62
367	A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2020 , 146, 79-89	4.8	11
366	Methylome analyses of three glioblastoma cohorts reveal chemotherapy sensitivity markers within DDR genes. <i>Cancer Medicine</i> , 2020 , 9, 8373-8385	4.8	7
365	Pleural metastasis of anaplastic meningioma. <i>Radiology Case Reports</i> , 2020 , 15, 2668-2671	1	0
364	The Association Between the Extent of Glioblastoma Resection and Survival in Light of MGMT Promoter Methylation in 326 Patients With Newly Diagnosed IDH-Wildtype Glioblastoma. <i>Frontiers in Oncology</i> , 2020 , 10, 1087	5.3	7
363	Noninvasive Characterization of Tumor Angiogenesis and Oxygenation in Bevacizumab-treated Recurrent Glioblastoma by Using Dynamic Susceptibility MRI: Secondary Analysis of the European Organization for Research and Treatment of Cancer 26101 Trial. <i>Radiology</i> , 2020 , 297, 164-175	20.5	7
362	Determining medical decision-making capacity in brain tumor patients: why and how?. <i>Neuro-Oncology Practice</i> , 2020 , 7, 599-612	2.2	9
361	Response to Letter to Editor. <i>Neuro-Oncology</i> , 2020 , 22, 1706-1707	1	1
360	cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading. <i>Brain Pathology</i> , 2020 , 30, 844-856	6	196
359	Predicting the 1p/19q Codeletion Status of Presumed Low-Grade Glioma with an Externally Validated Machine Learning Algorithm. <i>Clinical Cancer Research</i> , 2019 , 25, 7455-7462	12.9	40
358	Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications. <i>Neuro-Oncology</i> , 2019 , 21, 571-584	1	67
357	The RANO Leptomeningeal Metastasis Group proposal to assess response to treatment: lack of feasibility and clinical utility and a revised proposal. <i>Neuro-Oncology</i> , 2019 , 21, 648-658	1	50
356	The added value of health-related quality of life as a prognostic indicator of overall survival and progression-free survival in glioma patients: a meta-analysis based on individual patient data from randomised controlled trials. <i>European Journal of Cancer</i> , 2019 , 116, 190-198	7.5	11
355	Defining EGFR amplification status for clinical trial inclusion. <i>Neuro-Oncology</i> , 2019 , 21, 1263-1272	1	12
354	Association Between Supratotal Glioblastoma Resection and Patient Survival: A Systematic Review and Meta-Analysis. <i>World Neurosurgery</i> , 2019 , 127, 617-624.e2	2.1	23
353	Repeatability and reproducibility of relative cerebral blood volume measurement of recurrent glioma in a multicentre trial setting. <i>European Journal of Cancer</i> , 2019 , 114, 89-96	7.5	9
352	Imaging necrosis during treatment is associated with worse survival in EORTC 26101 study. <i>Neurology</i> , 2019 , 92, e2754-e2763	6.5	6

351	Anticonvulsant prophylaxis and steroid use in adults with metastatic brain tumors: summary of SNO and ASCO endorsement of the Congress of Neurological Surgeons guidelines. <i>Neuro-Oncology</i> , 2019 , 21, 424-427	1	14
350	Recent developments and future directions in adult lower-grade gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) consensus. <i>Neuro-Oncology</i> , 2019 , 21, 837-853	1	37
349	Automated quantitative tumour response assessment of MRI in neuro-oncology with artificial neural networks: a multicentre, retrospective study. <i>Lancet Oncology</i> , 2019 , 20, 728-740	21.7	160
348	Comparison of Biomarker Assays for : Implications for Precision Medicine in Patients with Glioblastoma. <i>Clinical Cancer Research</i> , 2019 , 25, 3259-3265	12.9	16
347	Temporal muscle thickness is an independent prognostic marker in patients with progressive glioblastoma: translational imaging analysis of the EORTC 26101 trial. <i>Neuro-Oncology</i> , 2019 , 21, 1587-1594	15.94	26
346	Differences in spatial distribution between WHO 2016 low-grade glioma molecular subgroups. <i>Neuro-Oncology Advances</i> , 2019 , 1, vdz001	0.9	4
345	Symptom clusters in newly diagnosed glioma patients: which symptom clusters are independently associated with functioning and global health status?. <i>Neuro-Oncology</i> , 2019 , 21, 1447-1457	1	19
344	Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastoma. <i>Journal of Neuro-Oncology</i> , 2019 , 144, 205-210	4.8	13
343	Barriers to accrual and enrollment in brain tumor trials. <i>Neuro-Oncology</i> , 2019 , 21, 1100-1117	1	25
342	Molecular targeted therapy of glioblastoma. <i>Cancer Treatment Reviews</i> , 2019 , 80, 101896	14.4	167
341	Evaluation of the Hippocampal Normal Tissue Complication Model in a Prospective Cohort of Low Grade Glioma Patients-An Analysis Within the EORTC 22033 Clinical Trial. <i>Frontiers in Oncology</i> , 2019 , 9, 991	5.3	15
340	Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial. <i>Neuro-Oncology</i> , 2019 , 21, 106-114	1	56
339	OS3.1 Antiepileptic drugs and their association with depression, anxiety and subjective cognitive impairment in glioma patients. <i>Neuro-Oncology</i> , 2019 , 21, iii8-iii8	1	78
338	OS3.5 Prescription medications in glioma patients and the prevalence of depression, anxiety and subjective cognitive impairment. <i>Neuro-Oncology</i> , 2019 , 21, iii9-iii9	1	78
337	Withdrawal of antiepileptic drugs in patients with low grade and anaplastic glioma after long-term seizure freedom: a prospective observational study. <i>Journal of Neuro-Oncology</i> , 2019 , 142, 463-470	4.8	14
336	How we treat patients with leptomeningeal metastases. <i>ESMO Open</i> , 2019 , 4, e000507	6	37
335	SURG-30. CLINICAL COURSE OF IDH-MUTATED LOW-GRADE GLIOMAS DURING THE POSTSURGICAL ACTIVE MONITORING PHASE: ASYMPTOMATIC PATIENTS, WELL CONTROLLED SEIZURES, BUT CONTINUOUS GROWTH OF TUMOR RESIDUES. <i>Neuro-Oncology</i> , 2019 , 21, vi245-vi246	1	78
334	How I treat anaplastic glioma without 1p/19q codeletion. <i>ESMO Open</i> , 2019 , 4, e000534	6	1

333	INNV-33. BARRIERS TO ACCRUAL AND ENROLLMENT IN BRAIN TUMOR TRIALS. <i>Neuro-Oncology</i> , 2019 , 21, vi137-vi137	1	10
332	NCOG-05. IMPACT OF ADDITIONAL RITUXIMAB TO STANDARD THERAPY ON COGNITIVE PERFORMANCES IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA PATIENTS. <i>Neuro-Oncology</i> , 2019 , 21, vi159-vi159	1	1
331	QOLP-03. MEASURING CHANGE IN HEALTH-RELATED QUALITY OF LIFE: THE ADDED VALUE OF ANALYSIS ON THE INDIVIDUAL PATIENT LEVEL IN GLIOMA PATIENTS IN CLINICAL DECISION MAKING. <i>Neuro-Oncology</i> , 2019 , 21, vi197-vi198	1	0
330	ACTR-39. PAMIPARIB IN COMBINATION WITH RADIATION THERAPY (RT) AND/OR TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED OR RECURRENT/REFRACTORY (R/R) GLIOBLASTOMA (GBM); PHASE 1B/2 STUDY UPDATE. <i>Neuro-Oncology</i> , 2019 , 21, vi21-vi22	1	6
329	ACTR-30. UPDATED EFFICACY AND SAFETY OF DABRAFENIB PLUS TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600E MUTATED HIGH-GRADE GLIOMA (HGG) AND LOW-GRADE GLIOMA (LGG). <i>Neuro-Oncology</i> , 2019 , 21, vi19-vi20	1	12
328	ACTR-11. SECOND INTERIM AND 1ST MOLECULAR ANALYSIS OF THE EORTC RANDOMIZED PHASE III INTERGROUP CATNON TRIAL ON CONCURRENT AND ADJUVANT TEMOZOLOMIDE IN ANAPLASTIC GLIOMA WITHOUT 1p/19q CODELETION. <i>Neuro-Oncology</i> , 2019 , 21, vi14-vi14	1	4
327	EANO-EURACAN clinical practice guideline for diagnosis, treatment, and follow-up of post-pubertal and adult patients with medulloblastoma. <i>Lancet Oncology</i> , 2019 , 20, e715-e728	21.7	31
326	LTBK-12. EORTC 26951, RANDOMIZED STUDY OF ADJUVANT PCV AFTER 59.4 GY RADIOTHERAPY: VERY LONG TERM FOLLOW-UP. <i>Neuro-Oncology</i> , 2019 , 21, vi285-vi285	1	0
325	QOLP-04. CALCULATING THE NET CLINICAL BENEFIT IN BRAIN TUMOR TRIALS BY COMBINING SURVIVAL AND HEALTH-RELATED QUALITY OF LIFE DATA USING TWO METHODS: QUALITY ADJUSTED SURVIVAL EFFECT SIZES AND JOINT MODELLING. <i>Neuro-Oncology</i> , 2019 , 21, vi198-vi198	1	78
324	P14.41 Temporal muscle thickness is an independent prognostic marker in patients with progressive glioblastoma: translational imaging analysis of the EORTC-26101 trial. <i>Neuro-Oncology</i> , 2019 , 21, iii76-iii76	1	78
323	Neuro-Oncology Clinical Debate: PCV or temozolomide in combination with radiation for newly diagnosed high-grade oligodendroglioma. <i>Neuro-Oncology Practice</i> , 2019 , 6, 17-21	2.2	3
322	Novel methods to diagnose leptomeningeal metastases in breast cancer. <i>Neuro-Oncology</i> , 2019 , 21, 428-439		7
321	Management of low-grade glioma: a systematic review and meta-analysis. <i>Neuro-Oncology Practice</i> , 2019 , 6, 249-258	2.2	24
320	Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study. <i>Lancet Oncology</i> , 2019 , 20, 216-228	21.7	92
319	On high-risk, low-grade glioma: What distinguishes high from low?. <i>Cancer</i> , 2019 , 125, 174-176	6.4	11
318	cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant. <i>Acta Neuropathologica</i> , 2018 , 135, 639-642	14.3	186
317	Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. <i>Acta Neuropathologica</i> , 2018 , 136, 153-166	14.3	162
316	Prognostic relevance of mutations and copy number alterations assessed with targeted next generation sequencing in IDH mutant grade II glioma. <i>Journal of Neuro-Oncology</i> , 2018 , 139, 349-357	4.8	15

315	Radiotherapy quality assurance for the RTOG 0834/EORTC 26053-22054/NCIC CTG CEC.1/CATNON intergroup trial "concurrent and adjuvant temozolomide chemotherapy in newly diagnosed non-1p/19q deleted anaplastic glioma": Individual case review analysis. <i>Radiotherapy and Oncology</i> , 2018 , 127, 292-298	5.3	8
314	Efficacy of intrathecal chemotherapy in patients with central nervous system involvement of hematological malignancies: a retrospective analysis. <i>Journal of Neuro-Oncology</i> , 2018 , 139, 117-123	4.8	3
313	The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033. <i>Acta Neuropathologica</i> , 2018 , 135, 601-615	14.3	54
312	cIMPACT-NOW update 1: Not Otherwise Specified (NOS) and Not Elsewhere Classified (NEC). <i>Acta Neuropathologica</i> , 2018 , 135, 481-484	14.3	78
311	Clinical trial design for local therapies for brain metastases: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. <i>Lancet Oncology, The</i> , 2018 , 19, e33-e42	21.7	27
310	Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. <i>Lancet Oncology, The</i> , 2018 , 19, e20-e32	21.7	63
309	The T2-FLAIR mismatch sign as an imaging marker for non-enhancing IDH-mutant, 1p/19q-intact lower-grade glioma: a validation study. <i>Neuro-Oncology</i> , 2018 , 20, 1393-1399	1	88
308	Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial. <i>European Journal of Cancer</i> , 2018 , 94, 168-178	7.5	19
307	The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis. <i>Neuro-Oncology</i> , 2018 , 20, 103-112	1	142
306	Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma. <i>Neuro-Oncology</i> , 2018 , 20, 838-847	1	42
305	Cognitive functioning and health-related quality of life in patients with newly diagnosed primary CNS lymphoma: a systematic review. <i>Lancet Oncology, The</i> , 2018 , 19, e407-e418	21.7	19
304	Pseudoprogression of brain tumors. <i>Journal of Magnetic Resonance Imaging</i> , 2018 , 48, 571	5.6	117
303	Flow cytometry shows added value in diagnosing lymphoma in brain biopsies. <i>Cytometry Part B - Clinical Cytometry</i> , 2018 , 94, 928-934	3.4	5
302	Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial. <i>Lancet Oncology, The</i> , 2018 , 19, 1170-1179	21.7	49
301	Grade II and III Oligodendroglioma and Astrocytoma. <i>Neurologic Clinics</i> , 2018 , 36, 467-484	4.5	19
300	Precision Medicine for Primary Central Nervous System Tumors: Are We There Yet?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018 , 38, 158-167	7.1	4
299	Clinical evaluation of a dedicated next generation sequencing panel for routine glioma diagnostics. <i>Acta Neuropathologica Communications</i> , 2018 , 6, 126	7.3	19
298	Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group. <i>Neuro-Oncology</i> , 2018 , 20, 897-906	1	26

297	Timing of radiotherapy in newly diagnosed glioblastoma: no need to rush?. <i>Neuro-Oncology</i> , 2018 , 20, 868-869	1	3
296	Does early resection of presumed low-grade glioma improve survival? A clinical perspective. <i>Journal of Neuro-Oncology</i> , 2017 , 133, 137-146	4.8	21
295	Comparison of 2D (RANO) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumab-a report from the BELOB trial. <i>Neuro-Oncology</i> , 2017 , 19, 853-861	1	19
294	European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. <i>Lancet Oncology, The</i> , 2017 , 18, e315-e329	21.7	599
293	The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria. <i>Neuro-Oncology</i> , 2017 , 19, 625-635	1	87
292	2017 ,		1
291	Varicella zoster virus encephalitis in a patient with a solid carcinoma: a case report. <i>Journal of Neurology</i> , 2017 , 264, 1281-1283	5.5	1
290	A clinical perspective on the 2016 WHO brain tumor classification and routine molecular diagnostics. <i>Neuro-Oncology</i> , 2017 , 19, 614-624	1	79
289	Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG. <i>Neuro-Oncology</i> , 2017 , 19, 1119-1126	1	82
288	Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study. <i>Cancer Chemotherapy and Pharmacology</i> , 2017 , 80, 1209-1217	3.5	80
287	Molecular and clinical heterogeneity of adult diffuse low-grade IDH wild-type gliomas: assessment of TERT promoter mutation and chromosome 7 and 10 copy number status allows superior prognostic stratification. <i>Acta Neuropathologica</i> , 2017 , 134, 957-959	14.3	61
286	NIMG-19. GLIOMA-LIKE INTRAPARENCHYMATOUS LESIONS ON MRI BRAIN IN ADULT NEUROFIBROMATOSIS TYPE 1 PATIENTS. <i>Neuro-Oncology</i> , 2017 , 19, vi146-vi146	1	78
285	Response Assessment in Neuro-Oncology Clinical Trials. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2439-2449.	2	168
284	Diffuse Infiltrating Oligodendroglioma and Astrocytoma. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2394-2401.	1	103
283	Imaging Correlates of Adult Glioma Genotypes. <i>Radiology</i> , 2017 , 284, 316-331	20.5	93
282	Evidence-based management of adult patients with diffuse glioma - Authors' reply. <i>Lancet Oncology, The</i> , 2017 , 18, e430-e431	21.7	4
281	Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. <i>Lancet, The</i> , 2017 , 390, 1645-1653	40	225
280	Lomustine and Bevacizumab in Progressive Glioblastoma. <i>New England Journal of Medicine</i> , 2017 , 377, 1954-1963	59.2	425

279	Fatigue in patients with low grade glioma: systematic evaluation of assessment and prevalence. <i>Journal of Neuro-Oncology</i> , 2017 , 133, 237-246	4.8	15
278	Antibody-drug conjugates in glioblastoma therapy: the right drugs to the right cells. <i>Nature Reviews Clinical Oncology</i> , 2017 , 14, 695-707	19.4	69
277	Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials. <i>Clinical Cancer Research</i> , 2017 , 23, 5745-5756	12.9	44
276	Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high-dose methotrexate, and R-DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study. <i>Hematological Oncology</i> , 2017 , 35, 497-503	1.3	15
275	Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials. <i>Neuro-Oncology</i> , 2017 , 19, 12-21	1	65
274	NIMG-01. DIFFUSION MRI PHENOTYPES PREDICT OVERALL SURVIVAL BENEFIT FROM ANTI-VEGF MONOTHERAPY IN GLIOBLASTOMA AT FIRST OR SECOND RELAPSE. <i>Neuro-Oncology</i> , 2017 , 19, vi142-vi143	1.43	78
273	Efficacy analysis of ABT-414 with or without temozolomide (TMZ) in patients (pts) with EGFR-amplified, recurrent glioblastoma (rGBM) from a multicenter, international phase I clinical trial.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2003-2003	2.2	7
272	Final results of the EORTC Brain Tumor Group randomized phase II TAVAREC trial on temozolomide with or without bevacizumab in 1st recurrence grade II/III glioma without 1p/19q co-deletion.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2009-2009	2.2	8
271	Tumoren van het zenuwstelsel 2017 , 499-512		
270	Leptomeningeal metastases: a RANO proposal for response criteria. <i>Neuro-Oncology</i> , 2017 , 19, 484-492	1	101
269	Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2017 , 19, 965-975	1	60
268	Incidence of pseudoprogression in low-grade gliomas treated with radiotherapy. <i>Neuro-Oncology</i> , 2017 , 19, 719-725	1	26
267	Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial. <i>Neuro-Oncology</i> , 2016 , 18, 388-400	1	102
266	Low-Grade Gliomas 2016 , 452-468.e3		1
265	Diagnostic Detection of Allelic Losses and Imbalances by Next-Generation Sequencing: 1p/19q Co-Deletion Analysis of Gliomas. <i>Journal of Molecular Diagnostics</i> , 2016 , 18, 775-786	5.1	52
264	Gene-Tailored Treatments for Brain Disorders: Challenges and Opportunities. <i>Public Health Genomics</i> , 2016 , 19, 170-7	1.9	2
263	Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial. <i>Cancer Research</i> , 2016 , 76, 525-34	10.1	70
262	Phase II part of EORTC study 26101: The sequence of bevacizumab and lomustine in patients with first recurrence of a glioblastoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2019-2019	2.2	11

261	P09.06 Withdrawal of antiepileptic drugs in glioma patients after long-term seizure freedom. <i>Neuro-Oncology</i> , 2016 , 18, iv61-iv61	1	2
260	Low-grade astrocytomas 2016 , 563-566		
259	Prevalence of changes in personality and behavior in adult glioma patients: a systematic review. <i>Neuro-Oncology Practice</i> , 2016 , 3, 222-231	2.2	10
258	Phase II Study of Radiotherapy and Temozolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082). <i>Clinical Cancer Research</i> , 2016 , 22, 4797-4806	12.9	77
257	A validated microRNA profile with predictive potential in glioblastoma patients treated with bevacizumab. <i>Molecular Oncology</i> , 2016 , 10, 1296-304	7.9	17
256	Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. <i>Lancet Oncology</i> , 2016 , 17, 1521-1532	21.7	294
255	Low-grade and anaplastic oligodendroglioma. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2016 , 134, 361-80	3	19
254	Chromosome 7 gain and DNA hypermethylation at the HOXA10 locus are associated with expression of a stem cell related HOX-signature in glioblastoma. <i>Genome Biology</i> , 2015 , 16, 16	18.3	65
253	Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomas. <i>Neuro-Oncology</i> , 2015 , 17, 935-41	1	98
252	The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: results of the randomised controlled phase 2 BELOB trial. <i>European Journal of Cancer</i> , 2015 , 51, 1321-30	7.5	33
251	Chemotherapy in glioma. <i>CNS Oncology</i> , 2015 , 4, 179-92	4	36
250	Evidence-Based Diagnostic Algorithm for Glioma: Analysis of the Results of Pathology Panel Review and Molecular Parameters of EORTC 26951 and 26882 Trials. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1943-50	2.2	13
249	Response Assessment in Neuro-Oncology (RANO): more than imaging criteria for malignant glioma. <i>Neuro-Oncology Practice</i> , 2015 , 2, 205-209	2.2	8
248	Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. <i>Neuro-Oncology</i> , 2015 , 17, 1188-98	1	224
247	Joint modeling of longitudinal health-related quality of life data and survival. <i>Quality of Life Research</i> , 2015 , 24, 795-804	3.7	18
246	Treatment of large low-grade oligodendroglial tumors with upfront procarbazine, lomustine, and vincristine chemotherapy with long follow-up: a retrospective cohort study with growth kinetics. <i>Journal of Neuro-Oncology</i> , 2015 , 121, 365-72	4.8	26
245	DNA damage response and anti-apoptotic proteins predict radiosensitization efficacy of HDAC inhibitors SAHA and LBH589 in patient-derived glioblastoma cells. <i>Cancer Letters</i> , 2015 , 356, 525-35	9.9	25
244	PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients. <i>Acta Neuropathologica Communications</i> , 2015 , 3, 88	7.3	27

243	ATCT-16CODEL (ALLIANCE-N0577; EORTC-26081/2208; NRG-1071; NCIC-CEC-2): PHASE III RANDOMIZED STUDY OF RT VS. RT + TMZ VS. TMZ FOR NEWLY DIAGNOSED 1p/19q-CODELETED ANAPLASTIC GLIOMA. ANALYSIS OF PATIENTS TREATED ON THE ORIGINAL PROTOCOL DESIGN. <i>Neuro-Oncology</i> , 2015 , 17, v4.4-v5	1	14
242	Chemotherapy for low-grade glioma: when, for whom, which regimen?. <i>Current Opinion in Neurology</i> , 2015 , 28, 633-938	7.1	28
241	Assessment methods and prevalence of cognitive dysfunction in patients with low-grade glioma: A systematic review. <i>Journal of Rehabilitation Medicine</i> , 2015 , 47, 481-8	3.4	30
240	Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial. <i>British Journal of Cancer</i> , 2015 , 113, 226-31	8.7	12
239	Neuro-oncology: The many challenges of treating elderly glioblastoma patients. <i>Nature Reviews Neurology</i> , 2015 , 11, 374-5	15	11
238	Oligodendroglioma: pathology, molecular mechanisms and markers. <i>Acta Neuropathologica</i> , 2015 , 129, 809-27	14.3	128
237	Response assessment criteria for brain metastases: proposal from the RANO group. <i>Lancet Oncology, The</i> , 2015 , 16, e270-8	21.7	472
236	Oligodendrogliomas: a short history of clinical developments. <i>CNS Oncology</i> , 2015 , 4, 281-5	4	4
235	Practice changing mature results of RTOG study 9802: another positive PCV trial makes adjuvant chemotherapy part of standard of care in low-grade glioma. <i>Neuro-Oncology</i> , 2014 , 16, 1570-4	1	85
234	Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , 2014 , 15, 1100-8	21.7	629
233	EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. <i>Lancet Oncology, The</i> , 2014 , 15, e395-403	21.7	498
232	Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. <i>Lancet Oncology, The</i> , 2014 , 15, 943-53	21.7	496
231	Withdrawal of antiepileptic drugs in glioma patients after long-term seizure freedom: design of a prospective observational study. <i>BMC Neurology</i> , 2014 , 14, 157	3.1	10
230	Bevacizumab alone or in combination with chemotherapy in glioblastomas?--authorsReply. <i>Lancet Oncology, The</i> , 2014 , 15, e473-4	21.7	3
229	Leptomeningeal metastasis: a Response Assessment in Neuro-Oncology critical review of endpoints and response criteria of published randomized clinical trials. <i>Neuro-Oncology</i> , 2014 , 16, 1176-85	1	116
228	MGMT testing--the challenges for biomarker-based glioma treatment. <i>Nature Reviews Neurology</i> , 2014 , 10, 372-85	15	316
227	AT-34CONSTRUCTION OF AN INTEGRATED DIAGNOSTIC ALGORITHM CONSISTING OF CONSENSUS HISTOLOGIC AND MOLECULAR PARAMETERS OF TWO EORTC TRIALS ON ANAPLASTIC GLIOMA. <i>Neuro-Oncology</i> , 2014 , 16, v16-v16	1	78
226	Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD). <i>Neuro-Oncology</i> , 2014 , 16 Suppl 7, vii36-47	1	38

225	Pros and cons of current brain tumor imaging. <i>Neuro-Oncology</i> , 2014 , 16 Suppl 7, vii2-11	1	43
224	High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2014 , 25 Suppl 3, iii93-101	10.3	357
223	Reply to M.C. Chamberlain. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2273-4	2.2	
222	Health-related quality of life and cognitive functioning in long-term anaplastic oligodendroglioma and oligoastrocytoma survivors. <i>Journal of Neuro-Oncology</i> , 2014 , 116, 161-8	4.8	67
221	Radiation therapy and concurrent plus adjuvant temsirolimus (CCI-779) versus chemoirradiation with temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2003-2003	2.2	10
220	A phase 1 study evaluating ABT-414 in combination with temozolomide (TMZ) for subjects with recurrent or unresectable glioblastoma (GBM).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2021-2021	2.2	11
219	Leptomeningeal metastases: A rano proposal for response criteria.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e13019-e13019	2.2	
218	Joint modeling of longitudinal health-related quality of life (HRQoL) data and survival.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2034-2034	2.2	
217	Interlaboratory comparison of IDH mutation detection. <i>Journal of Neuro-Oncology</i> , 2013 , 112, 173-8	4.8	54
216	New validated prognostic models and prognostic calculators in patients with low-grade gliomas diagnosed by central pathology review: a pooled analysis of EORTC/RTOG/NCCTG phase III clinical trials. <i>Neuro-Oncology</i> , 2013 , 15, 1568-79	1	77
215	Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. <i>Journal of Clinical Oncology</i> , 2013 , 31, 328-36	2.2	80
214	Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. <i>Lancet Oncology, The</i> , 2013 , 14, e396-406	21.7	92
213	Optimal management of elderly patients with glioblastoma. <i>Cancer Treatment Reviews</i> , 2013 , 39, 350-7	14.4	108
212	Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group. <i>Lancet Oncology, The</i> , 2013 , 14, e407-16	21.7	97
211	Molecular subtypes of glioma identified by genome-wide methylation profiling. <i>Genes Chromosomes and Cancer</i> , 2013 , 52, 665-74	5	21
210	Clinical neuropathology practice news 2-2013: immunohistochemistry pins IDH in glioma - molecular testing procedures under scrutiny 2013 , 32, 82-3		4
209	Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. <i>Journal of Clinical Oncology</i> , 2013 , 31, 344-50	2.2	800
208	New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. <i>European Journal of Cancer</i> , 2013 , 49, 3477-85	7.5	43

207	MGMT-STP27 methylation status as predictive marker for response to PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951. <i>Clinical Cancer Research</i> , 2013 , 19, 5513-22	12.9	89
206	Serum-free culture success of glial tumors is related to specific molecular profiles and expression of extracellular matrix-associated gene modules. <i>Neuro-Oncology</i> , 2013 , 15, 1684-95	1	39
205	Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3212-8	2.2	392
204	RTOG 9802: good wines need aging. <i>Journal of Clinical Oncology</i> , 2013 , 31, 653-4	2.2	8
203	Central nervous system recurrence of systemic lymphoma in the era of stem cell transplantation--an International Primary Central Nervous System Lymphoma Study Group project. <i>Haematologica</i> , 2013 , 98, 808-13	6.6	41
202	Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss) low-grade glioma: A randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2007-2007	2.2	28
201	How to use molecular markers when caring for a patient with brain cancer: 1P/19Q as a predictive and prognostic marker in the neuro-oncology clinic. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013 , 114-6	7.1	
200	Optimizing the identification of anaplastic oligodendroglioma patients that benefit from adjuvant PCV chemotherapy using the Illumina platform: A further report from EORTC study 26951.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2011-2011	2.2	1
199	Acute painful lumbosacral paresthesia after intrathecal rituximab. <i>Journal of Neurology</i> , 2012 , 259, 559-615	5	5
198	EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma. <i>Neuro-Oncology</i> , 2012 , 14, 1503-10	1	45
197	Phase 2 trial design in neuro-oncology revisited: a report from the RANO group. <i>Lancet Oncology</i> , 2012 , 13, e196-204	21.7	43
196	Increased rCBV in status epilepticus. <i>Journal of Neurology</i> , 2012 , 259, 1746-8	5.5	1
195	New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials. <i>European Journal of Cancer</i> , 2012 , 48, 1176-84	7.5	137
194	MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. <i>Acta Neuropathologica</i> , 2012 , 124, 547-60	14.3	213
193	EORTC topics in neurooncology: The long path from a focus on neurological complications of cancer towards molecularly defined trials and therapies in neurooncology. <i>European Journal of Cancer, Supplement</i> , 2012 , 10, 20-26	1.6	
192	Current treatment of low grade gliomas. <i>Memo - Magazine of European Medical Oncology</i> , 2012 , 5, 223-227	23	26
191	Identification of delta/notch-like epidermal growth factor-related receptor as the Tr antigen in paraneoplastic cerebellar degeneration. <i>Annals of Neurology</i> , 2012 , 71, 815-24	9.4	101
190	Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study. <i>Journal of Neuro-Oncology</i> , 2012 , 108, 195-200	4.8	27

189	Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial. <i>Acta Neuropathologica</i> , 2012 , 123, 841-52	14.3	68
188	Prognostic value of Ki67 index in anaplastic oligodendroglial tumours--a translational study of the European Organization for Research and Treatment of Cancer Brain Tumor Group. <i>Histopathology</i> , 2012 , 60, 885-94	7.3	38
187	A phase I study of LY317615 (enzastaurin) and temozolomide in patients with gliomas (EORTC trial 26054). <i>Neuro-Oncology</i> , 2012 , 14, 344-50	1	19
186	Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice. <i>Neuro-Oncology</i> , 2012 , 14 Suppl 4, iv100-8	1	120
185	Anaplastic oligodendroglial tumors. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2012 , 105, 467-84	3	3
184	Gene expression profiles of gliomas in formalin-fixed paraffin-embedded material. <i>British Journal of Cancer</i> , 2012 , 106, 538-45	8.7	13
183	Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. <i>Neurosurgery</i> , 2012 , 70, 234-43; discussion 243-4	3.2	159
182	Long-term follow-up results of EORTC 26951: A randomized phase III study on adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors (AOD).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2-2	2.2	16
181	Long-term follow-up results of EORTC 26951: A randomized phase III study on adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors (AOD).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2-2	2.2	
180	Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma?. <i>Lancet Oncology</i> , 2011 , 12, 83-91	21.7	167
179	Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. <i>Lancet Oncology</i> , 2011 , 12, 583-93	21.7	397
178	MGMT promoter hypermethylation is a frequent, early, and consistent event in astrocytoma progression, and not correlated with TP53 mutation. <i>Journal of Neuro-Oncology</i> , 2011 , 101, 405-17	4.8	22
177	Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951. <i>Journal of Neuro-Oncology</i> , 2011 , 103, 221-30	4.8	18
176	EBV related cerebral lymphoma in a leukemia patient treated with alemtuzumab. <i>Journal of Neurology</i> , 2011 , 258, 944-5	5.5	3
175	Addition of serum-containing medium to cerebrospinal fluid prevents cellular loss over time. <i>Journal of Neurology</i> , 2011 , 258, 1507-12	5.5	34
174	Cytoreductive surgery of glioblastoma as the key to successful adjuvant therapies: new arguments in an old discussion. <i>Acta Neurochirurgica</i> , 2011 , 153, 1211-8	3	134
173	Alpha-internexin expression predicts outcome in anaplastic oligodendroglial tumors and may positively impact the efficacy of chemotherapy: European organization for research and treatment of cancer trial 26951. <i>Cancer</i> , 2011 , 117, 3014-26	6.4	26
172	Peri-ictal pseudoprogression in patients with brain tumor. <i>Neuro-Oncology</i> , 2011 , 13, 775-82	1	27

171	First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response. <i>Neuro-Oncology</i> , 2011 , 13, 235-41	1	55
170	Reply to P. Farace et al. <i>Journal of Clinical Oncology</i> , 2011 , 29, e149-e149	2.2	
169	Reply to A.A. Brandes et al. <i>Journal of Clinical Oncology</i> , 2011 , 29, e247-e247	2.2	
168	Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group. <i>Annals of Oncology</i> , 2011 , 22, 2144-2149	10.3	30
167	Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. <i>Neurology</i> , 2011 , 77, 1156-64	6.5	223
166	A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. <i>Clinical Cancer Research</i> , 2011 , 17, 7148-55	12.9	93
165	Minimal clinically meaningful differences for the EORTC QLQ-C30 and EORTC QLQ-BN20 scales in brain cancer patients. <i>Annals of Oncology</i> , 2011 , 22, 2107-2112	10.3	112
164	Clinical trial end points for high-grade glioma: the evolving landscape. <i>Neuro-Oncology</i> , 2011 , 13, 353-61	1	90
163	Anaplastic Oligodendrogliomas and Mixed Gliomas 2011 , 233-248		
162	Tumoren van het zenuwstelsel 2011 , 501-512		
161	Primary central nervous system lymphoma in the elderly: a multicentre retrospective analysis. <i>British Journal of Haematology</i> , 2010 , 151, 179-84	4.5	20
160	The CASPR2 cell adhesion molecule functions as a tumor suppressor gene in glioma. <i>Oncogene</i> , 2010 , 29, 6138-48	9.2	22
159	Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1168-74	2.2	367
158	Bevacizumab and recurrent malignant gliomas: a European perspective. <i>Journal of Clinical Oncology</i> , 2010 , 28, e188-9; author reply e190-2	2.2	92
157	Sitimagene ceradenovec: a gene-based drug for the treatment of operable high-grade glioma. <i>Future Oncology</i> , 2010 , 6, 1691-710	3.6	23
156	Human chorionic gonadotropin treatment of anti-Hu-associated paraneoplastic neurological syndromes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010 , 81, 1341-4	5.5	23
155	EORTC study 26041-22041: phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma. <i>European Journal of Cancer</i> , 2010 , 46, 348-54	7.5	64
154	An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients. <i>European Journal of Cancer</i> , 2010 , 46, 1033-40	7.5	217

153	IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. <i>Clinical Cancer Research</i> , 2010 , 16, 1597-604	12.9	328
152	Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1963-72	2.2	2543
151	Neurolymphomatosis: an International Primary CNS Lymphoma Collaborative Group report. <i>Blood</i> , 2010 , 115, 5005-11	2.2	207
150	MGMT promoter methylation in malignant gliomas: ready for personalized medicine?. <i>Nature Reviews Neurology</i> , 2010 , 6, 39-51	15	538
149	Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician's perspective. <i>Acta Neuropathologica</i> , 2010 , 120, 297-304	14.3	323
148	Molecular diagnostics of gliomas: the clinical perspective. <i>Acta Neuropathologica</i> , 2010 , 120, 585-92	14.3	96
147	Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas. <i>Lancet Neurology</i> , 2010 , 9, 906-20	24.1	287
146	Integrated genomic profiling identifies candidate genes implicated in glioma-genesis and a novel LEO1-SLC12A1 fusion gene. <i>Genes Chromosomes and Cancer</i> , 2010 , 49, 509-17	5	20
145	Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma. <i>Human Mutation</i> , 2010 , 31, E1186-99	4.7	84
144	Oligodendrogliomas: molecular biology and treatment. <i>Oncologist</i> , 2009 , 14, 155-63	5.7	59
143	IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. <i>Neurology</i> , 2009 , 73, 1792-5	6.5	168
142	MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5881-6	2.2	203
141	Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951. <i>Neuro-Oncology</i> , 2009 , 11, 737-46	1	62
140	End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria. <i>Journal of Clinical Oncology</i> , 2009 , 27, 2905-8	2.2	203
139	Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. <i>Cancer Research</i> , 2009 , 69, 9065-72	10.1	437
138	Cognitive rehabilitation in patients with gliomas: a randomized, controlled trial. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3712-22	2.2	237
137	Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. <i>Journal of Clinical Oncology</i> , 2009 , 27, 1268-74	2.2	429
136	No evidence for the presence of HuD-specific T cells in the cerebrospinal fluid of patients with Hu-associated paraneoplastic neurological syndromes. <i>Journal of Neurology</i> , 2009 , 256, 279-82	5.5	9

135	Neurological adverse effects caused by cytotoxic and targeted therapies. <i>Nature Reviews Clinical Oncology</i> , 2009 , 6, 596-603	19.4	95
134	Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. <i>Lancet Oncology, The</i> , 2009 , 10, 459-66	21.7	5111
133	Pseudoprogression and pseudoresponse in the treatment of gliomas. <i>Current Opinion in Neurology</i> , 2009 , 22, 633-8	7.1	256
132	Chromosome 1p loss evaluation in anaplastic oligodendrogliomas. <i>Neuropathology</i> , 2008 , 28, 440-3	2	19
131	B and T cell imbalances in CSF of patients with Hu-antibody associated PNS. <i>Journal of Neuroimmunology</i> , 2008 , 195, 164-70	3.5	29
130	Adjuvant dibromodulcitol and BCNU chemotherapy in anaplastic astrocytoma: results of a randomised European Organisation for Research and Treatment of Cancer phase III study (EORTC study 26882). <i>European Journal of Cancer</i> , 2008 , 44, 1210-6	7.5	40
129	The management of cerebral metastasis from germ cell cancer; walking the tightrope. <i>European Journal of Cancer</i> , 2008 , 44, 1622-4	7.5	4
128	Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. <i>Lancet Oncology, The</i> , 2008 , 9, 29-38	21.7	407
127	Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. <i>Lancet Oncology, The</i> , 2008 , 9, 453-61	21.7	834
126	Frequently asked questions in the medical management of high-grade glioma: a short guide with practical answers. <i>Annals of Oncology</i> , 2008 , 19 Suppl 7, vii209-16	10.3	26
125	Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. <i>Journal of Clinical Oncology</i> , 2008 , 26, 4659-65	2.2	163
124	A novel tool to analyze MRI recurrence patterns in glioblastoma. <i>Neuro-Oncology</i> , 2008 , 10, 1019-24	1	63
123	Oligodendroglioma. <i>Critical Reviews in Oncology/Hematology</i> , 2008 , 66, 262-72	7	52
122	Incidence of central nervous system involvement in chronic lymphocytic leukemia and outcome to treatment. <i>Journal of Neurology</i> , 2008 , 255, 828-30	5.5	39
121	Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme: a report from the EORTC 26981/22981 NCI-C CE3 Intergroup Study. <i>Cancer</i> , 2008 , 112, 1337-44	6.4	37
120	Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoradiation with temozolomide. <i>Cancer</i> , 2008 , 113, 405-10	6.4	336
119	CSF flow cytometry greatly improves diagnostic accuracy in CNS hematologic malignancies. <i>Neurology</i> , 2007 , 68, 1674-9	6.5	177
118	Anaplastic oligodendroglioma and oligoastrocytoma. <i>Neurologic Clinics</i> , 2007 , 25, 1089-109, ix-x	4.5	39

117	The prognostic value of health-related quality-of-life data in predicting survival in glioblastoma cancer patients: results from an international randomised phase III EORTC Brain Tumour and Radiation Oncology Groups, and NCIC Clinical Trials Group study. <i>British Journal of Cancer</i> , 2007 , 97, 302-7	8.7	83
116	Hemangioblastomatosis in a patient with von Hippel-Lindau disease. <i>Journal of Neuro-Oncology</i> , 2007 , 82, 163-4	4.8	12
115	Identification of differentially regulated splice variants and novel exons in glial brain tumors using exon expression arrays. <i>Cancer Research</i> , 2007 , 67, 5635-42	10.1	77
114	Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for Research and Treatment of Cancer randomized clinical trial. <i>Journal of Clinical Oncology</i> , 2007 , 25, 5723-30	2.2	85
113	Prognostic value of health-related quality-of-life data in predicting survival in patients with anaplastic oligodendrogliomas, from a phase III EORTC brain cancer group study. <i>Journal of Clinical Oncology</i> , 2007 , 25, 5731-7	2.2	59
112	Molecular targeted therapies and chemotherapy in malignant gliomas. <i>Current Opinion in Oncology</i> , 2007 , 19, 598-605	4.2	40
111	Intratumoral distribution of 1p loss in oligodendroglial tumors. <i>Journal of Neuropathology and Experimental Neurology</i> , 2007 , 66, 1118-23	3.1	9
110	Panel review of anaplastic oligodendroglioma from European Organization For Research and Treatment of Cancer Trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome. <i>Journal of Neuropathology and Experimental Neurology</i> , 2007 , 66, 545-51	3.1	119
109	Predictive and prognostic markers in neuro-oncology. <i>Journal of Neuropathology and Experimental Neurology</i> , 2007 , 66, 1074-81	3.1	29
108	Case-referent comparison of cognitive functions in patients receiving haematopoietic stem-cell transplantation for haematological malignancies: two-year follow-up results. <i>European Journal of Cancer</i> , 2007 , 43, 2052-9	7.5	26
107	Treatment of newly diagnosed anaplastic gliomas. <i>European Journal of Cancer, Supplement</i> , 2007 , 5, 409-410	4.6	160
106	Randomized phase II trial of erlotinib (E) versus temozolomide (TMZ) or BCNU in recurrent glioblastoma multiforme (GBM): EORTC 26034. <i>Journal of Clinical Oncology</i> , 2007 , 25, 2005-2005	2.2	22
105	The incidence of pseudo-progression in a cohort of malignant glioma patients treated with chemo-radiation with temozolomide. <i>Journal of Clinical Oncology</i> , 2007 , 25, 2009-2009	2.2	20
104	Panel review of a set of anaplastic oligodendroglioma of EORTC trial 26951: interobserver variation, correlation with 1p/19q loss and clinical outcome. <i>FASEB Journal</i> , 2007 , 21, A26	0.9	
103	Identification of relevant prognostic histopathologic features in 69 intracranial ependymomas, excluding myxopapillary ependymomas and subependymomas. <i>Cancer</i> , 2006 , 106, 388-95	6.4	73
102	Diagnosis of neurolymphomatosis with FDG PET. <i>Neurology</i> , 2006 , 67, 722-3	6.5	40
101	Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. <i>Journal of Clinical Oncology</i> , 2006 , 24, 2563-9	2.2	377
100	Neurogenic pulmonary oedema in a patient with leptomeningeal carcinomatosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006 , 77, 1097	5.5	2

99	Changing paradigms--an update on the multidisciplinary management of malignant glioma. <i>Oncologist</i> , 2006 , 11, 165-80	5.7	316
98	Adjuvant treatment of high grade gliomas. <i>Annals of Oncology</i> , 2006 , 17 Suppl 10, x186-90	10.3	10
97	Neurocognitive functions and quality of life in haematological patients receiving haematopoietic stem cell grafts: a one-year follow-up pilot study. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2006 , 28, 283-93	2.1	33
96	Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. <i>Journal of Clinical Oncology</i> , 2006 , 24, 2715-22	2.2	583
95	Recent developments in the use of chemotherapy in brain tumours. <i>European Journal of Cancer</i> , 2006 , 42, 582-8	7.5	95
94	1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment. <i>European Journal of Cancer</i> , 2006 , 42, 2499-503	7.5	103
93	An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes. <i>Journal of Neurology</i> , 2006 , 253, 16-20	5.5	155
92	Surgical resection improves outcome in metastatic epidural spinal cord compression. <i>Lancet, The</i> , 2005 , 366, 609-10	4.0	18
91	Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. <i>Lancet, The</i> , 2005 , 366, 985-90	4.0	727
90	Health-related quality of life in patients with glioblastoma: a randomised controlled trial. <i>Lancet Oncology, The</i> , 2005 , 6, 937-44	21.7	246
89	Early or delayed radiotherapy for low-grade glioma? [Authors'Reply. <i>Lancet Oncology, The</i> , 2005 , 6, 922	21.7	
88	Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. <i>New England Journal of Medicine</i> , 2005 , 352, 987-96	59.2	13703
87	Assessment of pre-treatment cognitive performance in adult bone marrow or haematopoietic stem cell transplantation patients: a comparative study. <i>European Journal of Cancer</i> , 2005 , 41, 1007-16	7.5	31
86	Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine. <i>Cancer</i> , 2005 , 103, 802-9	6.4	115
85	Resolution of EBV(+) CNS lymphoma with appearance of CSF EBV-specific T cells. <i>Annals of Neurology</i> , 2005 , 58, 788-92	9.4	5
84	Intracranial granulocytic sarcoma (chloroma) may mimic a subdural hematoma. <i>Journal of Neurology</i> , 2005 , 252, 498-9	5.5	25
83	Optimal role of temozolomide in the treatment of malignant gliomas. <i>Current Neurology and Neuroscience Reports</i> , 2005 , 5, 198-206	6.6	142
82	Diagnostic value of OCT3/4 for pre-invasive and invasive testicular germ cell tumours. <i>Journal of Pathology</i> , 2005 , 206, 242-9	9.4	140

81	Prevention of chemotherapy-induced neuropathy: leukemia inhibitory factor. <i>Clinical Cancer Research</i> , 2005 , 11, 1691-3	12.9	17
80	Gene expression profiles associated with treatment response in oligodendrogliomas. <i>Cancer Research</i> , 2005 , 65, 11335-44	10.1	95
79	Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. <i>Journal of Clinical Oncology</i> , 2005 , 23, 5034-43	2.2	575
78	Low-molecular weight caldesmon as a potential serum marker for glioma. <i>Clinical Cancer Research</i> , 2005 , 11, 4388-92	12.9	42
77	Severe amnesia due to HHV-6 encephalitis after allogeneic stem cell transplantation. <i>European Neurology</i> , 2005 , 54, 233-4	2.1	16
76	Current and future trials of the EORTC brain tumor group. <i>Oncology Research and Treatment</i> , 2004 , 27, 246-50	2.8	14
75	Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas. <i>Neurology</i> , 2004 , 63, 904-66.5		71
74	Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. <i>Neurology</i> , 2004 , 63, 535-7	6.5	285
73	Diagnosis and management of oligodendroglioma. <i>Seminars in Oncology</i> , 2004 , 31, 645-52	5.5	27
72	The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study. <i>European Journal of Cancer</i> , 2004 , 40, 2726-33	7.5	204
71	Management of metastatic (parenchymal, leptomeningeal, and epidural) lesions. <i>Current Opinion in Oncology</i> , 2004 , 16, 309-13	4.2	7
70	Advances in the biology and treatment of oligodendrogliomas. <i>Current Opinion in Neurology</i> , 2004 , 17, 675-80	7.1	23
69	Concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM). Conclusive results of a randomized phase III trial by the EORTC Brain & RT Groups and NCIC Clinical Trials Group. <i>Journal of Clinical Oncology</i> , 2004 , 22, 2-2	2.2	26
68	Clinical prognostic factors affecting survival in patients with newly diagnosed Glioblastoma Multiforme (GBM). <i>Journal of Clinical Oncology</i> , 2004 , 22, 9599-9599	2.2	3
67	Cognitive status and quality of life after treatment for primary CNS lymphoma. <i>Neurology</i> , 2004 , 62, 5446.5		115
66	Adaptive inpatient dose escalation of cisplatin in combination with low-dose vp16 in patients with nonsmall cell lung cancer. <i>British Journal of Cancer</i> , 2003 , 88, 814-21	8.7	11
65	Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients. <i>British Journal of Cancer</i> , 2003 , 88, 1199-206	8.7	168
64	High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. <i>Journal of Clinical Oncology</i> , 2003 , 21, 4483-8	2.2	272

63	Recent developments in the molecular characterization and treatment of oligodendroglial tumors. <i>Neuro-Oncology</i> , 2003 , 5, 128-138	1	49
62	Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. <i>Brain</i> , 2003 , 126, 1409-18	11.2	406
61	Identification of tumor-related proteins by proteomic analysis of cerebrospinal fluid from patients with primary brain tumors. <i>Journal of Neuropathology and Experimental Neurology</i> , 2003 , 62, 855-62	3.1	86
60	Cisplatin-induced encephalopathy and seizures. <i>Anti-Cancer Drugs</i> , 2003 , 14, 443-6	2.4	41
59	The European Organisation for Research and Treatment of Cancer strategy for new drug development in brain tumors. <i>Seminars in Oncology</i> , 2003 , 30, 77-80	5.5	2
58	Can chemotherapy replace radiotherapy in low-grade gliomas? Time for randomized studies. <i>Seminars in Oncology</i> , 2003 , 30, 39-44	5.5	13
57	Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. <i>Cancer</i> , 2003 , 97, 1276-84	6.4	167
56	The role of chemotherapy in brain metastases. <i>European Journal of Cancer</i> , 2003 , 39, 2114-20	7.5	94
55	Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. <i>Journal of Clinical Oncology</i> , 2003 , 21, 2525-8	2.2	256
54	Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. <i>Annals of Oncology</i> , 2003 , 14, 599-602	10.3	129
53	European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme. <i>Annals of Oncology</i> , 2003 , 14, 1732-4	10.3	33
52	Cognitive functioning and quality of life in long-term adult survivors of bone marrow transplantation. <i>Cancer</i> , 2002 , 95, 183-92	6.4	116
51	Cerebral venous and sinus thrombosis with cerebrospinal fluid circulation block after the first methotrexate administration by lumbar puncture. <i>Neuroradiology</i> , 2002 , 44, 929-32	3.2	18
50	Increased levels of soluble CD27 in the cerebrospinal fluid are not diagnostic for leptomeningeal involvement by lymphoid malignancies. <i>Annals of Hematology</i> , 2002 , 81, 187-91	3	13
49	Survival and outcome in 73 anti-Hu positive patients with paraneoplastic encephalomyelitis/sensory neuronopathy. <i>Journal of Neurology</i> , 2002 , 249, 745-53	5.5	186
48	Prognostic factors for survival in adult patients with cerebral low-grade glioma. <i>Journal of Clinical Oncology</i> , 2002 , 20, 2076-84	2.2	703
47	Retreatment with dose-dense weekly cisplatin after previous cisplatin chemotherapy is not complicated by significant neuro-toxicity. <i>European Journal of Cancer</i> , 2002 , 38, 387-91	7.5	25
46	Dose-dense cisplatin/paclitaxel. a well-tolerated and highly effective chemotherapeutic regimen in patients with advanced ovarian cancer. <i>European Journal of Cancer</i> , 2002 , 38, 2005-13	7.5	32

45	A solitary spinal cord toxoplasma lesion after peripheral stem-cell transplantation. <i>Journal of Neurology</i> , 2001 , 248, 814-5	5.5	19
44	Temozolomide chemotherapy in recurrent oligodendroglioma. <i>Neurology</i> , 2001 , 57, 340-2	6.5	79
43	Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. <i>British Journal of Cancer</i> , 2001 , 84, 157-63	8.7	88
42	PCV chemotherapy for recurrent glioblastoma multiforme. <i>Neurology</i> , 2001 , 56, 1782	6.5	6
41	PCV chemotherapy for recurrent glioblastoma multiforme. <i>Neurology</i> , 2001 , 56, 118-20	6.5	93
40	New perspectives for the diagnosis and treatment of oligodendroglioma. <i>Expert Review of Anticancer Therapy</i> , 2001 , 1, 348-56	3.5	16
39	The diagnosis and management of brain metastases. <i>Current Opinion in Neurology</i> , 2001 , 14, 717-23	7.1	27
38	Increased incidence of neurological complications in patients receiving an allogeneic bone marrow transplantation from alternative donors. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2000 , 68, 36-40	5.5	66
37	Leptomeningeal metastasis after surgical resection of brain metastases. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1999 , 66, 225-7	5.5	67
36	Negative sural nerve biopsy in neurolymphomatosis. <i>Journal of Neurology</i> , 1999 , 246, 1159-63	5.5	47
35	The accumulation of topotecan in 9L glioma and in brain parenchyma with and without dexamethasone administration. <i>Journal of Neuro-Oncology</i> , 1999 , 42, 117-22	4.8	22
34	Phase II study of weekly dose-intensified cisplatin chemotherapy with oral etoposide in recurrent glioma. <i>Journal of Neuro-Oncology</i> , 1999 , 44, 59-64	4.8	9
33	Cyclosporine neurotoxicity: a review. <i>Journal of Neurology</i> , 1999 , 246, 339-46	5.5	349
32	Erythropoietin induced visual hallucinations after bone marrow transplantation. <i>Journal of Neurology</i> , 1999 , 246, 614-6	5.5	5
31	Spinal epidural abscess complicating chronic epidural analgesia in 11 cancer patients: clinical findings and magnetic resonance imaging. <i>Journal of Neurology</i> , 1999 , 246, 815-20	5.5	32
30	Glial fibrillary acidic protein and its fragments discriminate astrocytoma from oligodendroglioma. <i>Electrophoresis</i> , 1999 , 20, 1087-91	3.6	9
29	Genetic aberrations in oligodendroglial tumours: an analysis using comparative genomic hybridization (CGH). <i>Journal of Pathology</i> , 1999 , 188, 282-8	9.4	38
28	The effect of dexamethasone on the uptake of cisplatin in 9L glioma and the area of brain around tumor. <i>Journal of Neuro-Oncology</i> , 1998 , 37, 1-8	4.8	33

27	Outcome and complications of epidural analgesia in patients with chronic cancer pain. <i>Cancer</i> , 1998 , 83, 2015-2022	6.4	101
26	Phase II study on cisplatin and ifosfamide in recurrent high grade gliomas. <i>European Journal of Cancer</i> , 1998 , 34, 1570-4	7.5	10
25	Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. <i>Neurology</i> , 1998 , 51, 1140-5	6.5	165
24	Corticosteroid co-medication does not reduce the incidence and severity of neurotoxicity induced by docetaxel. <i>Anti-Cancer Drugs</i> , 1998 , 9, 759-64	2.4	17
23	Lhermitte® sign following chemotherapy with docetaxel. <i>Neurology</i> , 1998 , 50, 563-4	6.5	29
22	Clinical characteristics of severe peripheral neuropathy induced by docetaxel (Taxotere). <i>Annals of Oncology</i> , 1997 , 8, 187-90	10.3	71
21	Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin. <i>British Journal of Cancer</i> , 1997 , 75, 417-22	8.7	58
20	Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors. <i>Journal of Clinical Oncology</i> , 1997 , 15, 1071-9	2.2	59
19	A phase II study of weekly high-dose cisplatin combined with oral etoposide in advanced non-small-cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1997 , 40, 347-52	3.5	10
18	¹ H chemical shift imaging reveals loss of brain tumor choline signal after administration of Gd-contrast. <i>Magnetic Resonance in Medicine</i> , 1997 , 37, 222-5	4.4	118
17	Progression of paclitaxel-induced neuropathy following discontinuation of treatment. <i>Muscle and Nerve</i> , 1997 , 20, 750-2	3.4	44
16	^{99m} Tc-SPECT in the diagnosis of skull base metastasis. <i>Neurology</i> , 1997 , 48, 1326-30	6.5	11
15	Phosphorus-31 chemical shift imaging of metastatic tumors located in the spine region. <i>Investigative Radiology</i> , 1997 , 32, 344-50	10.1	4
14	Anterior cervical discectomy with or without fusion with acrylate. A randomized trial. <i>Spine</i> , 1996 , 21, 834-9; discussion 840	3.3	63
13	Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 1996 , 73, 1265-7	8.7	10
12	Peripheral neurotoxicity induced by docetaxel. <i>Neurology</i> , 1996 , 46, 104-8	6.5	106
11	EMG before and after cervical anterior discectomy. <i>Acta Neurologica Scandinavica</i> , 1995 , 92, 332-6	3.8	1
10	Neurolymphomatosis of the median nerve. <i>Neurology</i> , 1995 , 45, 1403-5	6.5	35

9	Neurotoxicity is not enhanced by increased dose intensities of cisplatin administration. <i>European Journal of Cancer</i> , 1995 , 31A, 678-81	7.5	22
8	Effect of an ACTH(4-9) analogue on cisplatin neuropathy of longstanding duration: a phase II study. <i>Clinical Neurology and Neurosurgery</i> , 1995 , 97, 139-41	2	3
7	Deafness, sensory neuropathy, and ovarian dysgenesis: a new syndrome or a broader spectrum of Perrault syndrome?. <i>American Journal of Medical Genetics Part A</i> , 1994 , 51, 81-2		26
6	Clinical course and risk factors of neurotoxicity following cisplatin in an intensive dosing schedule. <i>European Journal of Neurology</i> , 1994 , 1, 45-50	6	10
5	Paclitaxel (Taxol) induces cumulative mild neurotoxicity. <i>European Journal of Cancer</i> , 1994 , 30A, 1074-7	7.5	62
4	Prolonged remission of primary central nervous system lymphoma after discontinuation of steroid therapy. <i>Journal of Neuro-Oncology</i> , 1992 , 13, 257-9	4.8	7
3	Glial fibrillary acidic protein and its fragments discriminate astrocytoma from oligodendroglioma		507-512
2	Low Grade Astrocytoma		510-513
1	The epigenetic evolution of gliomas is determined by their IDH1 mutation status and treatment regimen		1